EMA Authorised: Sogroya (somapacitan) — Novo Nordisk A/S

View source ↗

Summary

EMA authorised Sogroya (somapacitan) from Novo Nordisk A/S for growth hormone-related indications in the EU, including adults with growth hormone deficiency.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Growth Hormone Deficiency

Drugs mentioned

• Sogroya (somapacitan)

Snippet

Status: Authorised. Therapeutic area: Growth. MAH: Novo Nordisk A/S. Decision date: 21/11/2025. Orphan medicine